Currently Viewing:
ACO & Emerging Healthcare Delivery Coalition® Spring 2017
Dr Mark Friedberg: How Practices Shifting to Value-Based Care Models Can Alleviate Burnout
November 16, 2017
Dr Frank James on the Role of Stigma in Addiction Treatment
November 15, 2017
Dr Darius Lakdawalla Discusses the Meaning and Measure of "Value" in Healthcare
September 13, 2017
Dr Darius Lakdawalla on the Willingness to Pay for a Cure
August 02, 2017
Dr Clifford Goodman: A Look at the Present and Future of Value Frameworks
July 22, 2017
Michael Griffin Describes Daughters of Charity's Long History of Leadership
July 21, 2017
Dr Sachin Jain Discusses CareMore's Community Partnerships, Internal Programs
July 18, 2017
Lee Barrett Outlines Best Practices for Healthcare Cybersecurity
July 15, 2017
Michael Griffin on Aligning Payers With Population Health and Social Determinants
July 12, 2017
Dr Clifford Goodman on Possible Drug Pricing Solutions Adapted From Abroad
July 11, 2017
Dr Sachin Jain on CareMore's Mission to Manage Chronic Disease From the Dentist's Chair
July 08, 2017
Michael Griffin Discusses Daughters of Charity's Ongoing Technology Initiatives
July 03, 2017
Lee Barrett: Increased Data Exchange in Value-Based Models Poses Cybersecurity Risks
June 29, 2017
Michael Griffin: Katrina's Lasting Effects on New Orleans and Its Healthcare System
June 22, 2017
Currently Reading
Dr Clifford Goodman Discusses Evidence-Based Drug Pricing as an Alternative to Legislative Controls
June 21, 2017
Lee Barrett on the Balance Between Strong Cybersecurity and Patient Access to Data
June 13, 2017
Dr Clifford Goodman on What to Look Forward to at the Fall 2017 ACO Coalition Meeting
June 09, 2017
Dr Sachin Jain: Discussion on Population Health Reveals Causes for Optimism
June 01, 2017
Dr Clifford Goodman: Why Focus on Value Will Persist Regardless of Changing Legislation
May 29, 2017

Dr Clifford Goodman Discusses Evidence-Based Drug Pricing as an Alternative to Legislative Controls

Constraining the cost of prescription drugs is a politically popular idea, but the same objective might be accomplished through evidence-based decision support for setting appropriate drug prices, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.


Constraining the cost of prescription drugs is a politically popular idea, but the same objective might be accomplished through evidence-based decision support for setting appropriate drug prices, according to Clifford Goodman, PhD, moderator at the ACO Coalition spring live meeting in Scottsdale, Arizona, and senior vice president and director at the Center for Comparative Effectiveness Research at the Lewin Group.

Transcript (slightly modified)

Drug pricing remains one issue with bipartisan agreement, but in the increasingly political environment, can we expect the 2 parties to agree on legislation to address drug costs?

We all like to think that drug prices can and should be lower, and that does include our politicians. From a political standpoint, it’s usually pretty good politics to say, “drug prices are too high for my constituents.” Who’s against that? So, it makes for good political fodder.

On the other hand, you might consider what could be accomplished in affecting drug pricing, and our same political people also have as their constituents, the industry, which is very important in many regions of our country. Industry and other stakeholders in the system that do benefit from the higher drug prices and will be resistant to that. You will hear arguments about how lowering drug prices might affect innovation and ultimately access to new therapies, and that there may be some downside to that.

Overall, what’s going to help yet again is this: if drug pricing discussion now and controversy can go back to the point of saying, well, what might be an appropriate price here? Is it merited by the data, the evidence that we have on effectiveness, on safety, and other aspects of patient outcomes. To the extent that that’s merited, and to the extent that we can have some sort of explicit understanding of the tradeoffs of health benefits from these and their relative cost, that will inform the discussion.

I think that those sorts of evidence-based analyses and considerations may even be more important than trying to impose any strict downward cost-cutting pressure or setting of drug prices beyond the kinds of constraints that we already have, for example in the Medicaid programs and so forth.

I don’t see very strong-armed drug legislation coming down the pike anytime soon, but I do see an expansion of the decision support in drug negotiations and management on a day-to-day basis of our pharmaceuticals, biologics, and so forth in clinical care situations.

 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!